Injection Articles
Benefit of Eloxatin chemo plus Avastin
7 February 2005
Japan stock market week to January 31
7 February 2005
Novartis launches Zometa in Japan
7 February 2005
Novo Nordisk's Norditropin NordiFlex debuts in USA
31 January 2005
First launch for Eyetech/Pfizer's Macugen in USA
31 January 2005
US ANDA filings "buy time for branded drugs"
24 January 2005
Teva gets FDA OK for fluconazole injection
24 January 2005
Paradigm acquires Amedic Pharma
17 January 2005
Serono's Saizen also available for adult GHD
17 January 2005
Alkermes expands Risperdal Consta capacity
17 January 2005
FDA accepts Spectrum's sumatriptan ANDA
17 January 2005
Taxotere cleared for two new indications
17 January 2005
ISTA debuts Vitrase in USA
10 January 2005
Macugen an effective therapy for AMD
10 January 2005
Serono completes enrollment in Rebif vs Copaxone trial
10 January 2005
FDA accepts Dacogen NDA for review
10 January 2005
Sicor re-acquires Calcitrol rights from aaiPharma
10 January 2005
Preclinical program for RhuDex nearing completion
10 January 2005
Isis to shares Macugen royalties for $24 M
10 January 2005
$12.5M placing by Aradigm
10 January 2005
Guilford completes sale and leaseback for $19.4M in net proceeds
10 January 2005
Eyetech due $90M as FDA clears Macugen
10 January 2005
CATs shareholders OK AstraZeneca subscription
10 January 2005
Further $7.8M financing for Introgen
20 December 2004
S-P's Peg-Intron launched in Japan
20 December 2004
Roche/GSK's IV Boniva filed in USA
20 December 2004
Cubist/Chiron's Cubicin filed in EU
13 December 2004
UPDATE: Guilford to acquire ProQuest for $7M
13 December 2004
Eyetech buys new facility
22 November 2004
Promising Ph II data for Abbott's ABT-874
22 November 2004
FDA fast-track for glufosfamide
22 November 2004
Positive data for Introgen's INGN 401
22 November 2004
New use for Novo Nordisk's Norditropin
15 November 2004
MedImmune initiates Ph III study of Numax
8 November 2004
EC clears Sanofi-Aventis' Taxotere for prostate cancer
8 November 2004
ISTA sees 3rd-qtr net loss widen
1 November 2004
Schering-Plough's Peg-Intron OKed in Japan
1 November 2004
EpiTan focuses on Melanotan, a potential blockbuster
1 November 2004
Tokyo pharma stocks - week to October 25
1 November 2004
QLT posts 27% rise in income for 3rd qtr
1 November 2004
Expanded US use for Serono's Luveris
25 October 2004
APP gets FDA OK for generic Paraplatin
25 October 2004
Pharmion raises sales guidance for Vidaza
4 October 2004
ISTA reacquires US rights for Vitrase
4 October 2004
Global analgesic mkt "to nearly double by 2010"
4 October 2004
New gel pill could provide alternative to injections
27 September 2004
Spectrum gains first ANDA approval, for ciprofloxacin
20 September 2004
Hemospherx starts West Nile Virus patient treatment in USA
13 September 2004
Novo Nordisk to appeal court's hGH patent rulings
13 September 2004
Eli Lilly/Amylin's exenatide shows promise as type 2 diabetes therapy
13 September 2004
Guilford plans two new trials for Aggrastat
30 August 2004
Aventis Taxotere gets OK for new use by FDA
23 August 2004
Macugen NDA accepted by FDA
23 August 2004
Cell Genesys' CG7870 starts combi trial
23 August 2004
FDA clears new delivery device for Aventis' Lantus
23 August 2004
Changes to UK childhood immunization program
16 August 2004
Guilford Pharma sees huge rise in 2nd-qtr loss
16 August 2004
Positive Phase I data for Astralis' Psoraxine
16 August 2004
Gilead sees sales jump 30% for 2nd-qtr
9 August 2004
AstraZeneca submits sNDA for Merrem IV
9 August 2004
Elan posts $117.6M 2nd-qtr net loss
9 August 2004
Eyetech sees losses grow on Macugen development costs
2 August 2004
FDA OK for liquid version of Synagis
2 August 2004
Millennium's 2nd-qtr net loss drops 50%
2 August 2004
Teva gains US appro for terbutaline
26 July 2004
Akzo's 2nd-qtr pharma sales slip further
26 July 2004
MGI Pharma's 2nd-qtr sales rocket to $46.9M
26 July 2004
EU green light for Schering AG's Nebido
19 July 2004
Promising new data for Xenova's TA-NIC
19 July 2004
Pharmacyclics initiates Ph II Xcytrin trial
12 July 2004
Tokyo pharma stocks - week to July 5
12 July 2004
Nabi to acquire full rights to Aloprim
5 July 2004
Stock Commentary - New York
5 July 2004
Isis earns $1M milestone on Macugen filing
28 June 2004
Onyvax' cancer vaccine shows promise
28 June 2004
Eyetech/Pfizer file NDA for Macugen
28 June 2004
Boost for French public hospitals
21 June 2004
Positive data from PI trial of ATL-1102 for MS
14 June 2004
Cubist and Chiron to file for EU appro on Cubicin
14 June 2004
Positive EU opinion for Aventis' Apidra
14 June 2004
AOB to acquire Chinese state-owned drugmaker
31 May 2004
FDA OKs Aventis' Taxotere for prostate cancer
24 May 2004
Bartek's Apokyn cleared by FDA
24 May 2004
Elan's 1st-qtr net loss plummets 52%
24 May 2004
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
